Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(8):548-549; doi:10.1093/jnci/dji123
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chambers, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chambers, S. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

EDITORIAL

Systematic Lymphadenectomy in Advanced Epithelial Ovarian Cancer: Two Decades of Uncertainty Resolved

Setsuko K. Chambers

Correspondence to: Setsuko K. Chambers, MD, Arizona Cancer Center, 1515 N. Campbell Ave., Tucson, AZ 85724-5024 (e-mail: schambers@azcc.arizona.edu).

The first 10% of the full text of this article appears below.

The overall long-term survival rates for patients with advanced epithelial ovarian cancer remain poor, despite modern advances in both surgery and chemotherapy. Maximal surgical cytoreduction (1) and primary platinum-based chemotherapy are powerful determinants of survival. For two decades, however, there has been a debate on the value of including systematic aortic and pelvic lymphadenectomy as part of the initial ovarian cancer debulking procedure in patients with advanced disease (2). It is clear that more than 50% of such patients will have positive lymph nodes and that the more extensive the intraperitoneal tumor burden, the higher the chance of retroperitoneal lymph node positivity. Although many investigators feel that it is the intrinsic biologic aggressiveness of the tumor (of which nodal metastasis represents just one marker), coupled with its chemosensitivity, that largely . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
P. Morice, P. Pautier, C. Lhomme, and D. Castaigne
Re: Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial
J Natl Cancer Inst, November 2, 2005; 97(21): 1620 - 1621.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. Querleu and G. Ferron
Re: Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial
J Natl Cancer Inst, November 2, 2005; 97(21): 1621 - 1621.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. K. Chambers, D. S. Alberts, and K. D. Hatch
RESPONSE: Re: Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial
J Natl Cancer Inst, November 2, 2005; 97(21): 1622 - 1623.
[Full Text] [PDF]